Bruker, a global life science analytical instrument company, agreed to acquire NanoString Technologies, a provider of life science tools for discovery and translational research, for $393m. “The acquisition of NanoString will add gene expression profiling and spatial transcriptomics solutions and products to Bruker’s spatial biology portfolio. NanoString’s innovative platforms are complementary to Bruker’s high-performance CellScape™ spatial proteomics platform. Over time we expect considerable, high-margin consumables pull-through, which is inherent in spatial and single-cell biology solutions,” Dr. Mark R. Munch, Bruker NANO Group President.